Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 10
2019 18
2020 21
2021 15
2022 14
2023 12
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

79 results

Results by year

Filters applied: . Clear all
Page 1
Safety and effectiveness of the radium-223-taxane treatment sequence in patients with metastatic castration-resistant prostate cancer in a global observational study (REASSURE).
Higano CS, Dizdarevic S, Logue J, Richardson T, George S, de Jong I, Tomaszewski JJ, Saad F, Miller K, Meltzer J, Sandström P, Verholen F, Tombal B, Sartor O. Higano CS, et al. Cancer. 2024 Jun 1;130(11):1930-1939. doi: 10.1002/cncr.35221. Epub 2024 Feb 10. Cancer. 2024. PMID: 38340349
Prognostic role of radiomics-based body composition analysis for the 1-year survival for hepatocellular carcinoma patients.
Saalfeld S, Kreher R, Hille G, Niemann U, Hinnerichs M, Öcal O, Schütte K, Zech CJ, Loewe C, van Delden O, Vandecaveye V, Verslype C, Gebauer B, Sengel C, Bargellini I, Iezzi R, Berg T, Klümpen HJ, Benckert J, Gasbarrini A, Amthauer H, Sangro B, Malfertheiner P, Preim B, Ricke J, Seidensticker M, Pech M, Surov A. Saalfeld S, et al. J Cachexia Sarcopenia Muscle. 2023 Oct;14(5):2301-2309. doi: 10.1002/jcsm.13315. Epub 2023 Aug 17. J Cachexia Sarcopenia Muscle. 2023. PMID: 37592827 Free PMC article.
Darolutamide in Spanish patients with nonmetastatic castration-resistant prostate cancer: ARAMIS subgroup analysis.
Carles J, Medina-Lopez RA, Puente J, Gómez-Ferrer Á, Nebra JC, Sáez Medina MI, Ribal MJ, Antolín AR, Álvarez-Ossorio JL, Suárez Novo JF, Agut CM, Srinivasan S, Ortiz J, Fizazi K. Carles J, et al. Future Oncol. 2023 Apr;19(12):819-828. doi: 10.2217/fon-2022-1131. Epub 2023 May 24. Future Oncol. 2023. PMID: 37222151 Free article. Clinical Trial.
79 results